Streetbeat News

NTBL

Notable Labs, Ltd.

https://www.notablelabs.com

Industry

Biotechnology

Notable Labs, Ltd., a clinical-stage platform therapeutics company, engages in developing predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient is likely to respond to that specific therapeutic. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and thus fast-track clinical development in this patient population. The company's pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor for acute myeloid leukemia (AML), pediatric leukemia, and myelodysplastic syndromes indications; and Fosciclopirox, a pro-drug of ciclopirox for AML. Notable Labs, Ltd. is headquartered in Foster City, California.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Wolfspeed shares rose 8.2% in pre-market trading despite missing earnings and revenue estimates for the fourth quarter and fiscal year. Several other stocks, including Staffing 360 Solutions and Mobix Labs, also saw significant pre-market movements.

Portfolio Pulse from Avi Kapoor

August 22, 2024 | 10:06 am

Notable Labs shares are trading lower following the company's announcement of progress in its Phase 2 volasertib program.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2024 | 11:52 am

Notable Labs announced progress for the Phase 2 Volasertib program after receiving 'clearance to proceed' from the FDA and agreement on the dosing plan for its Phase 2 clinical trial.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2024 | 11:33 am

Chardan Capital analyst Keay Nakae maintains a Buy rating on Notable Labs (NASDAQ:NTBL) but lowers the price target from $7 to $5.

Portfolio Pulse from Benzinga Newsdesk

May 16, 2024 | 4:09 pm

JMP Securities analyst Silvan Tuerkcan reiterated a Market Outperform rating on Notable Labs (NASDAQ:NTBL) and maintained a $9 price target.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 4:12 pm

Wall Street analysts have updated their price targets and ratings for several US-listed companies, including Centene Corporation, Veru Inc., JPMorgan Chase & Co., Notable Labs, Ltd., Charter Communications, Inc., PVH Corp., Cisco Systems, Inc., Masimo Corporation, Cadence Design Systems, Inc., and Lockheed Martin Corporation. These updates include both upgrades and downgrades, with specific changes to price targets and stock ratings.

Portfolio Pulse from Avi Kapoor

April 15, 2024 | 12:39 pm

Chardan Capital analyst Keay Nakae maintains a Buy rating on Notable Labs (NASDAQ:NTBL) but lowers the price target from $9 to $7.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 11:43 am

Juniper Networks, Inc. (JNPR) shares surged over 23% in pre-market trading due to reports of advanced acquisition discussions with Hewlett Packard Enterprise Co (HPE). HPE's stock fell 8.5% in pre-market trading as the potential deal, which could be worth around $13 billion, may be announced soon. Other stocks experienced significant movements in pre-market trading, with various gainers and losers listed.

Portfolio Pulse from Avi Kapoor

January 09, 2024 | 1:23 pm

JMP Securities analyst Silvan Tuerkcan has maintained a Market Outperform rating on Notable Labs (NASDAQ:NTBL) but has reduced the price target from $13 to $9.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 5:14 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.